Clinical Trial Update: Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating sintilimab plus a bevacizumab biosimilar as adjuvant therapy after resection of ruptured hepatocellular carcinoma is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab biosimilar (Bevacizumab)
• Tyvyt (Sintilimab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: RECRUITING